HIT Consultant May 17, 2022
What You Should Know:
– Character Biosciences (“Character”), a precision medicine platform for diseases of aging raises $18M in a new funding round led by Innovation Endeavors, alongside leading life sciences investors Section 32 and Catalio Capital Management. Formerly known as Clover Therapeutics, the company’s data-driven approach integrates genomics, deep phenotyping and machine learning for target and biomarker discovery.
– The company will use the funding to advance the frontiers of personalized medicine in genetically-defined diseases such as Age-related Macular Degeneration (AMD).
Precision Medicine Discovery Platform
Diseases are as diverse as the patients they impact. Founded in 2019, Character is a precision medicine platform that is unlocking the patterns of age-related diseases in people of...
Today's Sponsors
Today's Sponsor